Stephanie Pickett, MD
Urogynecology and Reconstructive Pelvic Surgery · Edmond, OKNPI 1255592952
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,360 of the $8,481 with a category attached, or 86.8%. It is spread thinly across 34 manufacturers, the largest accounting for just 19.4% — the pattern of someone who eats at a lot of different presentations. 2025 is the largest year on record at $2,346, 4.3 times the $545 reported in 2019.
Across 319 payments — averaging $26.59 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$2K
- Intuitive Surgical$1K
- Axonics, Inc.$706
- AbbVie$658
- Coloplast$564
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$498
- plus $3K from 28 others
Across 1 payment — averaging $787.50 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Medtronic$788
What the payments were for
- Travel & lodging$1,04512%
- Food & beverage$7,36087%
- Education$761%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Medtronic(2 entities) | 55 | $1,643 |
| Intuitive Surgical | 8 | $1,410 |
| Axonics, Inc. | 11 | $706 |
| AbbVie(2 entities) | 34 | $658 |
| Coloplast | 14 | $564 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 34 | $498 |
| Astellas Pharma US Inc | 21 | $366 |
| Sumitomo Pharma America, Inc. | 20 | $366 |
| Caldera Medical, Inc | 23 | $329 |
| Mayne Pharma Commercial LLC | 12 | $290 |
| Biotissue Holdings Inc. | 1 | $208 |
| Pfizer | 11 | $192 |
| Therapeuticsmd, Inc. | 10 | $153 |
| Urovant Sciences Inc | 8 | $133 |
| Bayer | 6 | $104 |
| Boston Scientific | 7 | $102 |
| Hologic Sales And Service, LLC | 4 | $97 |
| Avion Pharmaceuticals | 5 | $90 |
| Exeltis, USA Inc. | 4 | $69 |
| Evofem Biosciences, Inc. | 5 | $58 |
| Lupin Inc. | 3 | $52 |
| Millicent US Inc | 3 | $48 |
| Meditrina | 3 | $47 |
| Merck | 3 | $44 |
| Scynexis, Inc. | 3 | $40 |
| Myriad Women's Health, Inc. | 1 | $39 |
| Roche Diagnostics Corporation | 2 | $37 |
| Minerva Surgical, Inc | 2 | $28 |
| Vertex | 1 | $27 |
| Innovation Technologies Inc | 1 | $24 |
| Kerecis Limited | 1 | $19 |
| Duchesnay USA Incorporated | 1 | $15 |
| Sage Therapeutics, LLC | 1 | $13 |
| AMAG Pharmaceuticals, Inc. | 1 | $11 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
Too few urogynecology and reconstructive pelvic surgery providers in Oklahomato place this figure against a meaningful peer group, so we don't.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| MyrbetriqMirabegron | 499 | $375,441 |
| GemtesaVibegron | 254 | $194,494 |
| PremarinEstrogens, Conjugated | 124 | $54,993 |
| LinzessLinaclotide | 51 | $41,981 |
| Estradiol | 507 | $33,438 |
| EstringEstradiol | 40 | $21,634 |
| ImvexxyEstradiol | 36 | $11,878 |
| Trospium Chloride | 86 | $3,836 |
| Methenamine Hippurate | 34 | $2,269 |
| Colesevelam Hcl | 13 | $1,947 |
| Clobetasol Propionate | 32 | $1,389 |
| Estradiol (Once Weekly)Estradiol | 17 | $957 |
| Cephalexin | 112 | $952 |
| Trimethoprim | 22 | $659 |
| Ibuprofen | 87 | $465 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Astellas Pharma US IncMyrbetriq | $366 | $375,441499 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $366 | $194,494254 claims |
| PfizerPremarin, Estring | $192 | $76,628164 claims |
| AbbVieLinzess | $658 | $41,98151 claims |
| Therapeuticsmd, Inc.Imvexxy | $153 | $11,87836 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. There are too few urogynecology and reconstructive pelvic surgery providers in Oklahomaon file to place this against a meaningful peer group, so we don't.
Other urogynecology and reconstructive pelvic surgery in Edmond
- Dena O LearyEdmond$35K
- Edgar LeclaireEdmond$3K
- Benjamin BarenbergOklahoma City$33K
- Lieschen QuirozOklahoma City$32K
- Adam HareOklahoma City$9K
- Gini IkwuezunmaOklahoma City$7K
- Aleeza AbbasiOklahoma City$7K
- Arielle AllenOklahoma City$5K
- Kyle MockOklahoma City$2K
- Jameca PriceTulsa$2K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.